Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Successful Treatment of Systemic and Central Nervous System Post-Transplant Lymphoproliferative Disorder Without the Use of High-Dose Methotrexate or Radiation

Successful Treatment of Systemic and Central Nervous System Post-Transplant Lymphoproliferative Disorder Without the Use of High-Dose Methotrexate or Radiation PEDIATRIC BLOOD & CANCER Mahapatra, S., Chin, C. C., Iagaru, A., Heerema-McKenney, A., Twist, C. J. 2014; 61 (11): 2107-2109

Abstract

Post-transplant lymphoproliferative disorder (PTLD) describes a spectrum of conditions with highest incidence in the first year post-solid organ transplant in pediatric patients. Central nervous system (CNS) involvement with PTLD carries high mortality risk with no consensus on optimal therapeutic regimen. We present the case of a 7-year old heart transplant patient diagnosed with widespread monomorphic, CD20+, Epstein-Barr virus-positive PTLD, including CNS involvement. In addition to immunosuppression reduction and rituximab, she was treated with multiagent systemic and intrathecal chemotherapy. She achieved a prompt and complete clinical and radiologic remission, which has been sustained for over 46 months since diagnosis.

View details for DOI 10.1002/pbc.25129

View details for Web of Science ID 000342723300041